Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 5


Oral and Poster Abstracts Oral 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Current approach to FLT3 mutated AML Clinical Trials, AML, Clinical Research, Clinically Relevant, Diseases, Therapies, Myeloid Malignancies Nicholas J. Short, MD1, Courtney D. DiNardo, MD,...

  • 123456 Profile photo of Madelyn

    In a Phase I/II of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated AML (both FLT3-ITD and/or TKD ) had impressive response rates, especially in untreated patients (100% ORR new diagnosis, 67% R/R)) but is associated with significant cytopenias, even at lower doses.